A tumor-fighting gene can fail even when tests look normal
Original title: Characterisation of pathogenic PTEN variants that retain AKT suppressive activity.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done in animals, not people. Most findings at this stage never become treatments.
This was only done in cells and in mice, not in people.
The short version
A gene that helps hold back tumors can be broken in a way common lab tests do not catch.
What was studied. Scientists looked at changed forms of a gene called PTEN, which normally helps stop tumors. They tested the changed forms in cells, then bred mice carrying one change called R308C.
What they found. In cells, the changed gene still passed the usual test and still shut off a signal called AKT. But it did not stop glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary cells from pushing into nearby tissue. Mice with the change did not live as long as normal mice. About 40% got sick or grew lumps that could be felt.
What this means, and what it doesn't
What it could mean: PTEN may guard against tumors in more than one way. A gene test that only checks the AKT signal could miss a gene that is still broken. In time, this may help doctors read gene test results more clearly.
What it doesn't mean: This does not mean a new treatment. The work was done in cells and in mice, far from everyday care. No person was treated here, and nothing was shown to help patients. It is not a cure or a promise of one. Much more research in people would be needed first.
Source: PubMed, October 22, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.